{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:55:59Z","timestamp":1785524159388,"version":"3.56.0"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurogenetics"],"DOI":"10.1007\/s10048-026-00923-1","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T09:24:17Z","timestamp":1785317057000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Retrospective analysis of spinal muscular atrophy in tunisian population: phenotypic-genotypic associations and considerations for therapeutic advancement"],"prefix":"10.1007","volume":"27","author":[{"given":"Walid Sabri","family":"Hamadou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelbasset","family":"Amara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamza","family":"Chouk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saoussen","family":"Trabelsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayda","family":"Bennour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salma","family":"Najar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malek","family":"Hammedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amira","family":"Benzarti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorra","family":"H\u2019Mida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moez","family":"Gribaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"key":"923_CR1","doi-asserted-by":"publisher","first-page":"7S9","DOI":"10.1016\/S0929-693X(20)30270-0","volume":"27","author":"C Rouzier","year":"2020","unstructured":"Rouzier C, Chaussenot A, Paquis-Flucklinger V (2020) Molecular diagnosis and genetic counseling for spinal muscular atrophy (SMA). Arch Pediatr 27:7S9-7S14","journal-title":"Arch Pediatr"},{"key":"923_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22157896","volume":"22","author":"ME Butchbach","year":"2021","unstructured":"Butchbach ME (2021) Genomic variability in the survival motorneuron genes (SMN1 and SMN2): implications for spinal muscular atrophy phenotype and therapeutics development. Int J Mol Sci 22:7896","journal-title":"Int J Mol Sci"},{"key":"923_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/genes15101346","volume":"15","author":"A Trabacca","year":"2024","unstructured":"Trabacca A et al (2024) Update on inherited pediatric motor neuron diseases: clinical features and outcome. Genes (Basel) 15:1346","journal-title":"Genes (Basel)"},{"key":"923_CR4","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41572-022-00380-8","volume":"8","author":"E Mercuri","year":"2022","unstructured":"Mercuri E, Sumner CJ, Muntoni F et al (2022) Spinal muscular atrophy. Nat Rev Dis Primers 8:52","journal-title":"Nat Rev Dis Primers"},{"key":"923_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2025.1542396","volume":"16","author":"A Varone","year":"2025","unstructured":"Varone A, Esposito G, Bitetti I (2025) Spinal muscular atrophy in the era of new born screening: how the classification could change. Front Neurol 16:1542396","journal-title":"Front Neurol"},{"key":"923_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.prerep.2025.100031","volume":"3","author":"NK Mishra","year":"2025","unstructured":"Mishra NK, Mishra A (2025) Spinal muscular atrophy (SMA): treatment strategies, challenges and future prospects. Pharmacol Res-Rep 3:100031","journal-title":"Pharmacol Res-Rep"},{"key":"923_CR7","doi-asserted-by":"publisher","first-page":"7S15","DOI":"10.1016\/S0929-693X(20)30271-2","volume":"27","author":"F Audic","year":"2020","unstructured":"Audic F, Barnerias C (2020) Spinal muscular atrophy (SMA) type I (Werdnig Hoffmann disease). Arch Pediatr 27:7S15-7S17","journal-title":"Arch Pediatr"},{"key":"923_CR8","unstructured":"Prior TW, Leach ME, Finanger EL (2024) Spinal muscular atrophy. GeneReviews\u00ae\u00a0[Internet]"},{"key":"923_CR9","doi-asserted-by":"publisher","first-page":"7S23","DOI":"10.1016\/S0929-693X(20)30273-6","volume":"27","author":"E Salort-Campana","year":"2020","unstructured":"Salort-Campana E, Quijano-Roy S (2020) Clinical features of spinal muscular atrophy (SMA) type 3 (Kugelberg-Welander disease). Arch Pediatr 27:7S23-7S28","journal-title":"Arch Pediatr"},{"key":"923_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241511939","volume":"24","author":"H Nishio","year":"2023","unstructured":"Nishio H, Niba ETE, Saito T et al (2023) Spinal muscular atrophy: the past, present, and future of diagnosis and treatment. Int J Mol Sci 24:11939","journal-title":"Int J Mol Sci"},{"issue":"3","key":"923_CR11","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s00439-019-01983-0","volume":"138","author":"C Ruhno","year":"2019","unstructured":"Ruhno C, McGovern VL, Avenarius MR, Snyder PJ, Prior TW, Nery FC, Burghes AH (2019) Complete sequencing of the SMN2 gene in SMA patients detects SMN gene deletion junctions and variants in SMN2 that modify the SMA phenotype. Hum Genet 138(3):241\u2013256","journal-title":"Hum Genet"},{"key":"923_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2016.00007","volume":"3","author":"ME Butchbach","year":"2016","unstructured":"Butchbach ME (2016) Copy number variations in the survival motor neuron genes: implications for spinal muscular atrophy and other neurodegenerative diseases. Front Mol Biosci 3:7","journal-title":"Front Mol Biosci"},{"issue":"15","key":"923_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22157896","volume":"22","author":"ME Butchbach","year":"2021","unstructured":"Butchbach ME (2021) Genomic variability in the survival motor neuron genes (SMN1 and SMN2): implications for spinal muscular atrophy phenotype and therapeutics development. Int J Mol Sci 22(15):7896","journal-title":"Int J Mol Sci"},{"issue":"03","key":"923_CR14","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1055\/s-0042-1751302","volume":"9","author":"D Zhuri","year":"2022","unstructured":"Zhuri D, Gurkan H, Eker D, Karal Y, Yalcintepe S, Atli E, Atli EI (2022) Investigation on the effects of modifying genes on the spinal muscular atrophy phenotype. Global Med Genet 9(03):226\u2013236","journal-title":"Global Med Genet"},{"key":"923_CR15","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2020-0729","volume":"146","author":"MA Waldrop","year":"2020","unstructured":"Waldrop MA, Karingada C, Storey MA et al (2020) Gene therapy for spinal muscular atrophy: safety and early outcomes. Pediatrics 146:e20200729","journal-title":"Pediatrics"},{"key":"923_CR16","volume":"15","author":"T Ogbonmide","year":"2023","unstructured":"Ogbonmide T et al (2023) Gene therapy for spinal muscularatrophy (SMA): a review of current challenges and safety considerations for onasemnogeneabeparvovec (Zolgensma). Cureus 15:e36371","journal-title":"Cureus"},{"key":"923_CR17","doi-asserted-by":"publisher","first-page":"948","DOI":"10.29271\/jcpsp.2024.08.948","volume":"34","author":"B Chen","year":"2024","unstructured":"Chen B, Gong Y, Zhou T (2024) The impact of nusinersen and risdiplam on motorfunction for spinal muscular atrophy type 2 and 3: A meta-analysis. J Coll Physicians Surg Pak 34:948\u2013955","journal-title":"J Coll Physicians Surg Pak"},{"key":"923_CR18","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ejpn.2011.07.007","volume":"16","author":"A Amara","year":"2012","unstructured":"Amara A, Adala L, Charfeddine IB et al (2012) Correlation of SMN2, NAIP, p44, H4F5 and Occludin genes copy number with spinal muscular atrophy phenotype in Tunisian patients. Eur J Paediatr Neurol 16:167\u2013174","journal-title":"Eur J Paediatr Neurol"},{"key":"923_CR19","first-page":"101299","volume":"46","author":"S Nmer","year":"2026","unstructured":"Nmer S, Trhanint S, Sayel H, Chaouki S, Bouguenouch L, Ouldim K (2026) First combined analysis of SMN1, SMN2, and NAIP copy numbers in Moroccan SMA patients and their correlation with disease severity. Mol Genet Metabolism Rep 46:101299","journal-title":"Mol Genet Metabolism Rep"},{"issue":"21","key":"923_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13216402","volume":"13","author":"J Lamadrid-Gonz\u00e1lez","year":"2024","unstructured":"Lamadrid-Gonz\u00e1lez J, Castellar-Leones S, Contreras-Vel\u00e1squez JC, Berm\u00fadez V (2024) SMN2 copy number association with spinal muscular atrophy severity: insights from Colombian patients. J Clin Med 13(21):6402","journal-title":"J Clin Med"},{"issue":"1","key":"923_CR21","doi-asserted-by":"publisher","first-page":"2540463","DOI":"10.1080\/14767058.2025.2540463","volume":"38","author":"M Shboul","year":"2025","unstructured":"Shboul M, El-Khateeb M, Fathallah R, Al-Rashed K (2025) Outcomes of genetic testing and prenatal diagnosis of spinal muscular atrophy in Jordan. J Maternal-Fetal Neonatal Med 38(1):2540463","journal-title":"J Maternal-Fetal Neonatal Med"},{"issue":"2","key":"923_CR22","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1177\/22143602241301657","volume":"12","author":"B Aziz","year":"2025","unstructured":"Aziz B, Arif AA, Kazi K, Kirmani S, Ansar Z, Nasir A, Khan S (2025) Analysis of spinal muscular atrophy patients from the spinal muscular atrophy and muscular dystrophy registry of Pakistan. J Neuromuscul Dis 12(2):260\u2013270","journal-title":"J Neuromuscul Dis"},{"key":"923_CR23","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1055\/a-1801-3785","volume":"90","author":"MC Walter","year":"2022","unstructured":"Walter MC, Hiebeler M (2022) SpinaleMuskelatrophieimErwachsenenalter. Fortschr Neurol Psychiatr 90:421\u2013430","journal-title":"Fortschr Neurol Psychiatr"},{"key":"923_CR24","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S1474-4422(23)00419-2","volume":"23","author":"CJ Yeo","year":"2024","unstructured":"Yeo CJ, Tizzano EF, Darras BT (2024) Challenges and opportunities in spinal muscularatrophytherapeutics. Lancet Neurol 23:205\u2013218","journal-title":"Lancet Neurol"},{"key":"923_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-6-71","volume":"6","author":"A D'Amico","year":"2011","unstructured":"D\u2019Amico A, Mercuri E, Tiziano FD et al (2011) Spinal muscular atrophy. Orphanet J Rare Dis 6:71","journal-title":"Orphanet J Rare Dis"},{"key":"923_CR26","first-page":"E41","volume":"63","author":"MA Rochmah","year":"2017","unstructured":"Rochmah MA, Shima AI, Harahap NIF et al (2017) Gender effects on the clinical phenotype in Japanese patients with spinal muscular atrophy. Kobe J Med Sci 63:E41","journal-title":"Kobe J Med Sci"},{"key":"923_CR27","doi-asserted-by":"publisher","first-page":"847","DOI":"10.3233\/JND-230011","volume":"10","author":"J Sun","year":"2023","unstructured":"Sun J, Harrington MA, Porter B (2023) Sex difference in spinal muscular atrophy patients\u2014are males more vulnerable? J Neuromuscul Dis 10:847\u2013867","journal-title":"J Neuromuscul Dis"},{"key":"923_CR28","unstructured":"https:\/\/www.ins.tn\/sites\/default\/files-ftp3\/files\/2025-09\/PROD-DEMOGRAPHIE-BULLETIN-FR_0.pdf (consulted June 2026)"},{"key":"923_CR29","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1136\/jnnp-2022-ABN.406","volume":"93","author":"L Maggi","year":"2022","unstructured":"Maggi L, Bello L, Bonanno S et al (2022) Adults with spinal muscular atrophy: A large-scale natural history study shows gender effect on disease. J NeurolNeurosurg Psychiatry 93:1253\u20131261","journal-title":"J NeurolNeurosurg Psychiatry"},{"key":"923_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-01771-y","volume":"16","author":"A Lusakowska","year":"2021","unstructured":"Lusakowska A et al (2021) Observation of the natural course of type 3 spinal muscular atrophy: data from the Polish registry of spinal muscular atrophy. Orphanet J Rare Dis 16:150","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"923_CR31","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s13023-021-01771-y","volume":"16","author":"A Lusakowska","year":"2021","unstructured":"Lusakowska A, Lusakowska A, Jedrzejowska M, Kaminska A, Janiszewska K, Grochowski P, Zimowski J, Kostera-Pruszczyk A (2021) Observation of the natural course of type 3 spinal muscular atrophy: data from the polish registry of spinal muscular atrophy. Orphanet Journal of Rare Diseases 16(1):150","journal-title":"Orphanet Journal of Rare Diseases"},{"key":"923_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0671-8","volume":"12","author":"IE Verhaart","year":"2017","unstructured":"Verhaart IE, Robertson A, Wilson IJ et al (2017) Prevalence, incidence and carrier frequency of 5q\u2013linked spinal muscular atrophy\u2013a literature review. Orphanet J Rare Dis 12:124","journal-title":"Orphanet J Rare Dis"},{"key":"923_CR33","doi-asserted-by":"publisher","first-page":"5192","DOI":"10.1007\/s00415-020-10332-5","volume":"268","author":"G Querin","year":"2021","unstructured":"Querin G, Lenglet T, Debs R et al (2021) Development of new outcome measures for adult SMA type III and IV: a multimodal longitudinal study. J Neurol 268:5192\u20131802","journal-title":"J Neurol"},{"issue":"5","key":"923_CR34","first-page":"256","volume":"102","author":"N Mezzi","year":"2023","unstructured":"Mezzi N, Abassi N, Fatnassi F, Abdelhak S, Romdhane L (2023) Consanguinty and its impact on health and genome dynamic: An example from Tunisia. Tunis Med 102(5):256","journal-title":"Tunis Med"},{"key":"923_CR35","first-page":"65","volume":"2","author":"S Azam","year":"2025","unstructured":"Azam S, Batool F (2025) Spinal muscular atrophies in Pakistan: A complex genetic disease. J Basic EmergSci 2:65\u201378","journal-title":"J Basic EmergSci"},{"key":"923_CR36","doi-asserted-by":"publisher","first-page":"294","DOI":"10.4103\/0028-3886.98514","volume":"60","author":"S Ibrahim","year":"2012","unstructured":"Ibrahim S, Moatter T, Saleem AF (2012) Spinal muscular atrophy: clinical spectrum and genetic mutations in Pakistani children. Neurol India 60:294\u2013298","journal-title":"Neurol India"},{"key":"923_CR37","first-page":"1857","volume":"29","author":"SMA Haider","year":"2022","unstructured":"Haider SMA, Bashir T, Ali W et al (2022) Patterns of inheritance and diagnostic features of spinal muscular atrophy, in areas with high rates of consanguineous marriages. Prof Med J 29:1857\u20131861","journal-title":"Prof Med J"},{"key":"923_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s43856-024-00548-1","volume":"4","author":"F Rabea","year":"2024","unstructured":"Rabea F, El Naofal M, Chekroun I et al (2024) Spinal muscular atrophy genetic epidemiology and the case for premarital genomic screening in Arab populations. Commun Med 4:119","journal-title":"Commun Med"},{"key":"923_CR39","doi-asserted-by":"publisher","first-page":"e2049","DOI":"10.1002\/mgg3.2049","volume":"10","author":"M Al Jumah","year":"2022","unstructured":"Al Jumah M, Al Rajeh S, Eyaid W et al (2022) Spinal muscular atrophy carrier frequency in Saudi Arabia. Mol Genet Genomic Med 10:e2049","journal-title":"Mol Genet Genomic Med"},{"key":"923_CR40","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1002\/ajmg.a.33771","volume":"155","author":"L Romdhane","year":"2011","unstructured":"Romdhane L, Abdelhak S (2011) Genetic diseases in the Tunisian population. Am J Med Genet A 155:238\u2013267","journal-title":"Am J Med Genet A"},{"key":"923_CR41","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1093\/hmg\/ddaf035","volume":"34","author":"MM Zwartkruis","year":"2025","unstructured":"Zwartkruis MM et al (2025) A de novo deletion underlying spinal muscular atrophy: Implications for carrier testing and genetic counseling. Hum Mol Genet 34:894\u2013904","journal-title":"Hum Mol Genet"},{"issue":"7S","key":"923_CR42","first-page":"18","volume":"27","author":"C Canc\u00e8s","year":"2020","unstructured":"Canc\u00e8s C, Richelme C, Barnerias C et al (2020) Clinical features of spinal muscular atrophy (SMA) type 2. Arch Pediatr 27(7S):18-7S22","journal-title":"Arch Pediatr"},{"issue":"5875","key":"923_CR43","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1126\/science.1155085","volume":"320","author":"GE Oprea","year":"2008","unstructured":"Oprea GE, Kr\u00f6ber S, McWhorter ML, Rossoll W, M\u00fcller S, Krawczak M, Wirth B (2008) Plastin 3 is a protective modifier of autosomal recessive spinal muscular atrophy. Science 320(5875):524\u2013527","journal-title":"Science"},{"key":"923_CR44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0033572","volume":"7","author":"TO Crawford","year":"2012","unstructured":"Crawford TO, Paushkin SV, Kobayashi DT et al (2012) Evaluation of SMN protein, transcript, and copy number in the biomarkers for spinal muscular atrophy (BforSMA) clinical study. PLoS One 7:e33572","journal-title":"PLoS One"},{"key":"923_CR45","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.nmd.2018.01.003","volume":"28","author":"M Calucho","year":"2018","unstructured":"Calucho M, Bernal S, Al\u00edas L et al (2018) Correlation between SMA type and SMN2 copy number revisited: an analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases. Neuromuscul Disord 28:208\u2013215","journal-title":"Neuromuscul Disord"},{"key":"923_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s12881-019-0935-3","volume":"20","author":"J Jiang","year":"2019","unstructured":"Jiang J, Huang J, Gu J et al (2019) Genomic analysis of a spinal muscular atrophy (SMA) discordant family identifies a novel mutation in TLL2, an activator of growth differentiation factor 8 (myostatin): a case report. BMC Med Genet 20:204","journal-title":"BMC Med Genet"},{"key":"923_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1308296","volume":"15","author":"C Dosi","year":"2024","unstructured":"Dosi C, Masson R (2024) The impact of three SMN2 gene copies on clinical characteristics and effect of disease-modifying treatment in patients with spinal muscular atrophy: a systematic literature review. Front Neurol 15:1308296","journal-title":"Front Neurol"},{"key":"923_CR48","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1080\/14656566.2019.1595585","volume":"20","author":"M Riessland","year":"2019","unstructured":"Riessland M (2019) Is there hope for spinal muscular atrophy synthetic pharmacotherapy? Expert Opin Pharmacother 20:1049\u20131052","journal-title":"Expert Opin Pharmacother"},{"key":"923_CR49","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.omtn.2020.12.027","volume":"23","author":"AM Winkelsas","year":"2021","unstructured":"Winkelsas AM et al (2021) Targeting the 5\u2032 untranslatedregion of SMN2 as a therapeutic strategy for spinal muscular atrophy. Molecular Therapy Nucleic Acids 23:731\u2013742","journal-title":"Molecular Therapy Nucleic Acids"},{"key":"923_CR50","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1080\/17460441.2022.2149733","volume":"18","author":"B Torroba","year":"2023","unstructured":"Torroba B et al (2023) RNA-based drug discovery for spinal muscular atrophy: a story of small molecules and antisense oligonucleotides. Expert Opin Drug Discov 18:181\u2013192","journal-title":"Expert Opin Drug Discov"},{"key":"923_CR51","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1080\/14737175.2023.2268276","volume":"23","author":"Y Lakhina","year":"2023","unstructured":"Lakhina Y, Boulis NM, Donsante A (2023) Current and emerging targeted therapies for spinal muscular atrophy. Expert Rev Neurother 23:1189\u20131199","journal-title":"Expert Rev Neurother"},{"key":"923_CR52","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/S1474-4422(23)00502-1","volume":"23","author":"MA Farrar","year":"2024","unstructured":"Farrar MA, Kariyawasam DS (2024) Deciphering spinal muscular atrophy: the need for more research. Lancet Neurol 23:134\u2013136","journal-title":"Lancet Neurol"},{"key":"923_CR53","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/0092-8674(95)90461-1","volume":"80","author":"N Roy","year":"1995","unstructured":"Roy N, Mahadevan MS, McLean M et al (1995) The gene for neuronal apoptosis inhibitory protein is partially deleted in individuals with spinal muscular atrophy. Cell 80:167\u2013178","journal-title":"Cell"},{"key":"923_CR54","first-page":"27","volume":"13","author":"EJ Ahn","year":"2017","unstructured":"Ahn EJ, Yum MS, Kim EH et al (2017) Genotype\u2013phenotype correlation of SMN1 and NAIP deletions in Korean patients with spinal muscular atrophy. J ClinNeurol 13:27\u201331","journal-title":"J ClinNeurol"},{"key":"923_CR55","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1093\/hmg\/9.17.2479","volume":"9","author":"R G\u00f6tz","year":"2000","unstructured":"G\u00f6tz R, Karch C, Digby MR et al (2000) The neuronal apoptosis inhibitory protein suppresses neuronal differentiation and apoptosis in PC12 cells. Hum Mol Genet 9:2479\u20132489","journal-title":"Hum Mol Genet"},{"key":"923_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-30449-7","volume":"13","author":"S Savad","year":"2023","unstructured":"Savad S, Ashrafi MR, Samadaian N et al (2023) A comprehensive overview of SMN and NAIP copy numbers in Iranian SMA patients. Sci Rep 13:3202","journal-title":"Sci Rep"},{"key":"923_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-024-76815-x","volume":"14","author":"A Khanbazi","year":"2024","unstructured":"Khanbazi A, Beheshtian M, Azad M et al (2024) Comprehensive copy number analysis of spinal muscular atrophy among the Iranian population. Sci Rep 14:1\u201311","journal-title":"Sci Rep"},{"key":"923_CR58","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1002\/mus.21350","volume":"40","author":"B Elsheikh","year":"2009","unstructured":"Elsheikh B, Prior T, Zhang X et al (2009) An analysis of disease severity based on SMN2 copy number in adults with spinal muscular atrophy. Muscle Nerve 40:652\u2013656","journal-title":"Muscle Nerve"},{"key":"923_CR59","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1136\/jnnp-2016-314292","volume":"88","author":"RI Wadman","year":"2017","unstructured":"Wadman RI et al (2017) Association of motor milestones, SMN2 copy and outcome in spinal muscular atrophy types 0\u20134. J Neurol Neurosurg Psychiatry 88:365\u2013367","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"923_CR60","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1177\/0883073814553271","volume":"30","author":"YJ Qu","year":"2015","unstructured":"Qu YJ, Ge XS, Bai JL, Wang LW, Cao YY, Lu YY, Song F (2015) Association of copy numbers of survival motor neuron gene 2 and neuronal apoptosis inhibitory protein gene with the natural history in a Chinese spinal muscular atrophy cohort. J Child Neurol 30(4):429\u2013436","journal-title":"J Child Neurol"},{"issue":"3","key":"923_CR61","doi-asserted-by":"publisher","first-page":"e18809","DOI":"10.1097\/MD.0000000000018809","volume":"99","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, He J, Zhang Y, Li L, Tang X, Wang L, Zhu B (2020) The analysis of the association between the copy numbers of survival motor neuron gene 2 and neuronal apoptosis inhibitory protein genes and the clinical phenotypes in 40 patients with spinal muscular atrophy: Observational study. Medicine 99(3):e18809","journal-title":"Medicine"},{"key":"923_CR62","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s00439-002-0828-x","volume":"111","author":"S Ogino","year":"2002","unstructured":"Ogino S, Wilson RB (2002) Genetic testing and risk assessment for spinal muscular atrophy (SMA). Hum Genet 111:477\u2013500","journal-title":"Hum Genet"},{"issue":"9","key":"923_CR63","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s00415-025-13314-7","volume":"272","author":"S Corti","year":"2025","unstructured":"Corti S, Ottoboni L, Sansone V (2025) Advancing personalized spinal muscular atrophy care: matching the right biomarker to the right patient at the right time. J Neurol 272:605","journal-title":"J Neurol"},{"key":"923_CR64","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1093\/hmg\/6.2.229","volume":"6","author":"TA Carter","year":"1997","unstructured":"Carter TA, B\u00f6nnemann CG, Wang CH et al (1997) A multicopy transcription-repair gene, BTF2p44, maps to the SMA region and demonstrates SMA associated deletions. Hum Mol Genet 6:229\u2013236","journal-title":"Hum Mol Genet"},{"key":"923_CR65","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1101\/gad.14.3.349","volume":"14","author":"SJ Ara\u00fajo","year":"2000","unstructured":"Ara\u00fajo SJ, Tirode F, Coin F et al (2000) Nucleotide excision repair of DNA with recombinant human proteins: definition of the minimal set of factors, active forms of TFIIH, and modulation by CAK. Genes Dev 14:349\u2013359","journal-title":"Genes Dev"},{"key":"923_CR66","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/1753","volume":"20","author":"JM Scharf","year":"1998","unstructured":"Scharf JM, Endrizzi MG, Wetter A et al (1998) Identification of a candidate modifying gene for spinal muscular atrophy by comparative genomics. Nat Genet 20:83\u201386","journal-title":"Nat Genet"},{"key":"923_CR67","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.gene.2012.12.109","volume":"518","author":"J He","year":"2013","unstructured":"He J, Zhang QJ, Lin QF et al (2013) Molecular analysis of SMN1, SMN2, NAIP, GTF2H2, and H4F5 genes in 157 Chinese patients with spinal muscular atrophy. Gene 518:325\u2013329","journal-title":"Gene"},{"key":"923_CR68","first-page":"1","volume":"12","author":"M Oskoui","year":"2017","unstructured":"Oskoui M et al (2017) The natural history of spinal muscular atrophy: A review of the literature. Orphanet J Rare Dis 12:1\u201313","journal-title":"Orphanet J Rare Dis"},{"key":"923_CR69","doi-asserted-by":"publisher","DOI":"10.52965\/001c.24934","volume":"13","author":"AN Edinoff","year":"2021","unstructured":"Edinoff AN, Nguyen LH, Odisho AS et al (2021) The antisense oligonucleotide nusinersen for treatment of spinal muscular atrophy. Orthop Rev 13:24934","journal-title":"Orthop Rev"},{"key":"923_CR70","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","volume":"20","author":"JW Day","year":"2021","unstructured":"Day JW, Finkel RS, Chiriboga CA et al (2021) Onasemnogeneabeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol 20:284\u2013293","journal-title":"Lancet Neurol"},{"key":"923_CR71","doi-asserted-by":"publisher","first-page":"77","DOI":"10.18071\/isz.76.0077","volume":"76","author":"K Szab\u00f3-Taylor","year":"2023","unstructured":"Szab\u00f3-Taylor K, Moln\u00e1r JM (2023) A spinalisizomatrophiaszem\u00e9lyreszabottter\u00e1pi\u00e1slehet\u0151s\u00e9gei. Ideggyogy Sz 76:77\u201394","journal-title":"Ideggyogy Sz"},{"key":"923_CR72","first-page":"eabb6871","volume":"13","author":"L Kong","year":"2021","unstructured":"Kong L, Valdivia DO, Simon CM et al (2021) Impaired prenatal motor axon development necessitates early therapeutic intervention in severe SMA. SciTransl Med 13:eabb6871","journal-title":"SciTransl Med"},{"key":"923_CR73","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41434-024-00503-8","volume":"32","author":"B Chongmelaxme","year":"2025","unstructured":"Chongmelaxme B, Yodsurang V, Vichayachaipat P et al (2025) Gene-based therapy for the treatment of spinal muscular atrophy types 1 and 2: a systematic review and meta-analysis. Gene Ther 32:301\u2013330","journal-title":"Gene Ther"},{"key":"923_CR74","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0302860","volume":"19","author":"BD Fernandes","year":"2024","unstructured":"Fernandes BD, Krug BC, Rodrigues FDA et al (2024) Efficacy and safety of onasemnogeneabeparvovec for the treatment of patients with spinal muscular atrophy type 1: a systematic review with meta analysis. PLoS One 19:e0302860","journal-title":"PLoS One"},{"issue":"9","key":"923_CR75","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1080\/14712598.2022.2066471","volume":"22","author":"HJ McMillan","year":"2022","unstructured":"McMillan HJ, Proud CM, Farrar MA, Alexander IE, Muntoni F, Servais L (2022) Onasemnogeneabeparvovec for the treatment of spinal muscular atrophy. Expert Opin Biol Ther 22(9):1075\u20131090","journal-title":"Expert Opin Biol Ther"},{"key":"923_CR76","first-page":"100973","volume":"35","author":"T Sawada","year":"2023","unstructured":"Sawada T, Kido J, Yae Y et al (2023) Gene therapy for spinal muscular atrophy is considerably effective when administered as early as possible after birth. Mol Genet Metab Rep 35:100973","journal-title":"Mol Genet Metab Rep"},{"key":"923_CR77","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1212\/WNL.0000000000201294","volume":"99","author":"G Costamagna","year":"2022","unstructured":"Costamagna G, Govoni A, Wise A et al (2022) Bridging the gap: gene therapy in a patient with spinal muscular atrophy type 1. Neurology 99:952\u2013956","journal-title":"Neurology"},{"key":"923_CR78","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci13101419","volume":"13","author":"Y Qiao","year":"2023","unstructured":"Qiao Y, Chi Y, Gu J et al (2023) Safety and efficacy of nusinersen and risdiplam for spinal muscular atrophy: a systematic review and meta-analysis of randomized controlled trials. Brain Sci 13:1419","journal-title":"Brain Sci"},{"key":"923_CR79","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1056\/NEJMc2300802","volume":"392","author":"RS Finkel","year":"2025","unstructured":"Finkel RS, Hughes SH, Parker J et al (2025) Risdiplam for prenataltherapy of spinal muscularatrophy. N Engl J Med 392:1138\u20131140","journal-title":"N Engl J Med"},{"key":"923_CR80","doi-asserted-by":"publisher","first-page":"awaf123","DOI":"10.1093\/brain\/awaf123","volume":"148","author":"EF Tizzano","year":"2025","unstructured":"Tizzano EF, Lindner G, Chilcott E et al (2025) In utero therapy for spinal muscular atrophy: Closer to clinical translation. Brain 148:awaf123","journal-title":"Brain"},{"key":"923_CR81","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1002\/pd.6228","volume":"42","author":"ME Schwab","year":"2022","unstructured":"Schwab ME et al (2022) Investigating attitudes toward prenatal diagnosis and fetal therapy for spinal muscular atrophy. Prenat Diagn 42:1409\u20131419","journal-title":"Prenat Diagn"},{"key":"923_CR82","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1357476","volume":"15","author":"BB Zhou","year":"2024","unstructured":"Zhou BB, Chen X, Zhang C et al (2024) Analysis of spinal muscular atrophy carrier screening results in 32,416 pregnant women and 7,231 prepregnant women. Front Neurol 15:1357476","journal-title":"Front Neurol"},{"key":"923_CR83","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s42466-021-00162-9","volume":"4","author":"S Jablonka","year":"2022","unstructured":"Jablonka S, Hennlein L, Sendtner M (2022) Therapy development for spinal muscular atrophy: Perspectives for muscular dystrophies and neurodegenerative disorders. Neurol Res Pract 4:2","journal-title":"Neurol Res Pract"},{"key":"923_CR84","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15061764","volume":"15","author":"CA Ren\u00e9","year":"2023","unstructured":"Ren\u00e9 CA, Parks RJ (2023) Expanding the availability of onasemnogeneabeparvovec to older patients: the evolving treatment landscape for spinal muscular atrophy. Pharmaceutics 15:1764","journal-title":"Pharmaceutics"},{"key":"923_CR85","doi-asserted-by":"publisher","DOI":"10.52965\/001c.25579","volume":"13","author":"J Kakazu","year":"2021","unstructured":"Kakazu J, Walker NL, Babin KC et al (2021) Risdiplam for the use of spinal muscular atrophy. Orthop Rev 13:25579","journal-title":"Orthop Rev"},{"key":"923_CR86","volume":"14","author":"R Vezzoli","year":"2025","unstructured":"Vezzoli R, Bottai D, Adami R (2025) Managing spinal muscular atrophy: a look at the biology and treatment strategies. Biology (Basel) 14:977","journal-title":"Biology (Basel)"},{"key":"923_CR87","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1002\/jcsm.12542","volume":"11","author":"H Zhou","year":"2020","unstructured":"Zhou H et al (2020) Myostatin inhibition in combination with antisense oligonucleotide therapy improves outcomes in spinal muscular atrophy. J Cachexia Sarcopenia Muscle 11:768\u2013782","journal-title":"J Cachexia Sarcopenia Muscle"}],"container-title":["Neurogenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10048-026-00923-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10048-026-00923-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10048-026-00923-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:33:13Z","timestamp":1785519193000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10048-026-00923-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":87,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["923"],"URL":"https:\/\/doi.org\/10.1007\/s10048-026-00923-1","relation":{},"ISSN":["1364-6753"],"issn-type":[{"value":"1364-6753","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]},"assertion":[{"value":"15 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"52"}}